Kodiak Sciences Inc.
Business
Kodiak Sciences Inc. develops retinal therapeutics using its proprietary Antibody Biopolymer Conjugate (ABC) platform to treat major causes of blindness. The company's lead candidate is tarcocimab (Zenkuda), an anti-VEGF therapy designed for extended durability, with Phase 3 studies completed or enrolling in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. Kodiak also advances KSI-501, a bispecific anti-IL-6/VEGF therapy, and KSI-101 for macular edema secondary to inflammation, while expanding its platform to conjugate small molecules (ABCD platform) for glaucoma and geographic atrophy. The company retains all global rights to its product candidates and operates a dedicated commercial-scale manufacturing facility.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 182 | 126 | 206 | 268 | 217 | |
| General and administrative | 52 | 61 | 71 | 74 | 50 | |
| Total operating expenses | 234 | 187 | 277 | 341 | 267 | |
| Loss from operations | −234 | −187 | −277 | −341 | −267 | |
| Interest income | 5 | 11 | 17 | 7 | 298,000 | |
| Interest expense | 0 | 0 | −13,000 | −18,000 | −47,000 | |
| Other income (expense), net | −96,000 | −506,000 | 110,000 | 503,000 | −190,000 | |
| Net loss | −230 | −176 | −261 | −334 | −267 | |
| Net loss per share common share, basic | −4.32 | −3.35 | −4.97 | −6.39 | −5.16 | |
| Net loss per share common share, diluted | −4.32 | −3.35 | −4.97 | −6.39 | −5.16 | |
| Weighted-average shares of common stock outstanding used in computing net loss per common share, basic | 53 | 53 | 52 | 52 | 52 | |
| Weighted-average shares of common stock outstanding used in computing net loss per common share, diluted | 53 | 53 | 52 | 52 | 52 | |
| Change in unrealized gains (losses) related to available-for-sale debt securities, net of tax | 0 | 0 | 1 | −1 | −53,000 | |
| Total other comprehensive income (loss) | 0 | 0 | 1 | −1 | −53,000 | |
| Comprehensive loss | −230 | −176 | −259 | −335 | −267 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 210 | 168 | 286 | 190 | 732 | |
| Prepaid expenses and other current assets | 5 | 4 | 4 | 7 | 3 | |
| Total current assets | 215 | 172 | 289 | 486 | 735 | |
| Restricted cash | 6 | 6 | 6 | 6 | 6 | |
| Property and equipment, net | 85 | 102 | 120 | 56 | 41 | |
| Operating lease right-of-use asset | 37 | 47 | 55 | 59 | 67 | |
| Other assets | 9 | 9 | 9 | 59 | 55 | |
| Total assets | 352 | 336 | 479 | 667 | 904 | |
| Accounts payable | 13 | 4 | 14 | 9 | 12 | |
| Accrued and other current liabilities | 21 | 11 | 18 | 33 | 48 | |
| Operating lease liability | 12 | 11 | 10 | 10 | 4 | |
| Total current liabilities | 46 | 26 | 42 | 52 | 65 | |
| Long-term operating lease liability | 47 | 60 | 72 | 78 | 76 | |
| Liability related to sale of future royalties | 100 | 100 | 100 | 100 | 100 | |
| Long-term deposit | 2 | 0 | — | — | — | |
| Total liabilities | 194 | 185 | 214 | 230 | 241 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value -10,000,000 shares authorized; none issued | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value -490,000,000 shares authorized; 61,758,454 and 52,726,916 shares issued and outstanding, respectively | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | |
| Additional paid-in capital | 1,716 | 1,479 | 1,418 | 1,330 | 1,222 | |
| Accumulated deficit | −1,559 | −1,329 | −1,153 | −892 | −558 | |
| Total stockholders equity | 157 | 150 | 266 | 436 | 663 | |
| Total liabilities and stockholders equity | 352 | 336 | 479 | 667 | 904 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 18 | 19 | 18 | 4 | 1 | |
| Stock-based compensation | 59 | 60 | 89 | 106 | 61 | |
| Non-cash lease impairment expense | 2 | 0 | 0 | — | — | |
| Net accretion of discount on marketable securities | 0 | 0 | −846,000 | −1 | 25,000 | |
| Settlement of derivative contracts | 0 | 355,000 | 0 | −616,000 | 0 | |
| Amortization of operating lease right-of-use asset | 8 | 8 | 8 | 7 | 8 | |
| Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item | 20,000 | 0 | 6,000 | — | — | |
| Prepaid expenses and other current assets | −891,000 | −60,000 | 8 | −3 | −270,000 | |
| Other assets | 59,000 | −12,000 | 426,000 | 7 | 1 | |
| Accounts payable | 8 | −10 | 6 | 2 | −2 | |
| Accrued and other current liabilities | 9 | −7 | −13 | −2 | 14 | |
| Operating lease liability | −11 | −11 | −9 | 8 | 2 | |
| Long-term deposit | 2 | 0 | 0 | — | — | |
| Net cash provided by (used in) operating activities | −136 | −117 | −154 | −207 | −182 | |
| Purchase of property and equipment | −506,000 | −375,000 | −41 | −37 | −17 | |
| Deposits on property and equipment | 0 | −25,000 | −77,000 | −10 | −46 | |
| Purchase of marketable securities | 0 | 0 | −49 | −428 | 0 | |
| Maturities of marketable securities | 0 | 0 | 340 | 138 | 25 | |
| Settlement of derivative contracts | 0 | −355,000 | 0 | 616,000 | — | |
| Net cash provided by (used in) investing activities | −506,000 | −755,000 | 249 | −337 | −39 | |
| Cash in-transit for stock option exercises | 5 | 394,000 | 60,000 | 2 | 8 | |
| Proceeds from ESPP | 180,000 | 107,000 | 182,000 | 174,000 | 484,000 | |
| Principal payments of tenant improvement allowance payable | 0 | 0 | −211,000 | −49,000 | −45,000 | |
| Net cash provided by financing activities | 178 | 501,000 | 31,000 | 2 | 8 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 42 | −118 | 95 | −541 | −213 | |
| Cash paid for interest | 0 | 0 | 13,000 | 18,000 | 22,000 | |
| Purchase of property and equipment under accounts payable and accruals | 878,000 | 50,000 | 0 | 3 | 21 | |
| Reclassification of deposits to property and equipment | 0 | 25,000 | 44 | 5 | 2 | |
| Unpaid offering costs | 303,000 | 0 | 0 | 0 | 0 | |
| Cash in-transit for stock option exercises | 201,000 | 0 | 0 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Kodiak Sciences Inc.'s CIK number?
Kodiak Sciences Inc.'s SEC CIK number is 0001468748 (1468748). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Kodiak Sciences Inc.'s SEC filings?
All of Kodiak Sciences Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Kodiak Sciences Inc. last report earnings?
Kodiak Sciences Inc. (KOD) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-211811). This is Kodiak Sciences Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Kodiak Sciences Inc.'s most recent earnings 8-K?
Kodiak Sciences Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-211811. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Kodiak Sciences Inc.'s latest earnings 8-K →
Look up any company's CIK number →